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ABSTRACT
Background Adoptive transfer of engineered T cells 
has shown remarkable success in B- cell malignancies. 
However, the most common strategy of targeting lineage- 
specific antigens can lead to undesirable side effects. 
Also, a substantial fraction of patients have refractory 
disease. Novel treatment approaches with more precise 
targeting may be an appealing alternative. Oncogenic 
somatic mutations represent ideal targets because of 
tumor specificity. Mutation- derived neoantigens can be 
recognized by T- cell receptors (TCRs) in the context of 
MHC–peptide presentation.
Methods Here we have generated T- cell lines from 
healthy donors by autologous in vitro priming, targeting 
a missense mutation on the adaptor protein MyD88, 
changing leucine at position 265 to proline (MyD88 
L265P), which is one of the most common driver mutations 
found in B- cell lymphomas.
Results Generated T- cell lines were selectively reactive 
against the mutant HLA- B*07:02- restricted epitope but 
not against the corresponding wild- type peptide. Cloned 
TCRs from these cell lines led to mutation- specific and 
HLA- restricted reactivity with varying functional avidity. 
T cells engineered with a mutation- specific TCR (TCR- T 
cells) recognized and killed B- cell lymphoma cell lines 
characterized by intrinsic MyD88 L265P mutation. 
Furthermore, TCR- T cells showed promising therapeutic 
efficacy in xenograft mouse models. In addition, initial 
safety screening did not indicate any sign of off- target 
reactivity.
Conclusion Taken together, our data suggest that 
mutation- specific TCRs can be used to target the MyD88 
L265P mutation, and hold promise for precision therapy 
in a significant subgroup of B- cell malignancies, possibly 
achieving the goal of absolute tumor specificity, a long 
sought- after dream of immunotherapy.
INTRODUCTION
Recently, clinical studies of adoptive T- cell 
therapy (ATT) using chimeric antigen 
receptor T (CAR- T) cell therapy against the 
B- cell antigen CD19 have achieved remark-
able success and have shown response in 
around 50% of refractory and relapsed 
patients with diffuse large B- cell lymphoma 
(DLBCL).1 2 Similar strategies have been 
developed targeting other B- cell lineage 
antigens such as CD20, CD22 and BCMA 
(B- cell maturation antigen).3–5 However, 
tumor escape by modulating surface expres-
sion of the target antigen is a limitation 
of this strategy, leading to relapse in up to 
50% of patients treated with CD19 CAR- T 
cells.6 7 Furthermore, although being much 
more specific than standard chemotherapy, 
CD19 CAR- based ATT is lineage- specific 
rather than truly cancer- specific, as major 
parts of the B- cell compartment including 
normal B lymphocytes are eliminated. This 
frequently leads to severe B- cell aplasia that 
may cause morbidity or requirement for long- 
term immunoglobulin substitution and/or 
antibiotic prophylaxis.8
Surface antigens druggable by antibodies 
or antibody derivatives are only rarely tumor- 
specific, as oncogenic mutations occur 
mostly in intracellular proteins regulating 
cell proliferation and survival.9 In contrast to 
CAR- based strategies, T- cell receptor (TCR)- 
based ATT relies on classical TCR recogni-
tion of processed antigen- derived epitopes 
presented in the context of MHC (major 
histocompatibility complex) molecules. The 
ability to target any protein independent 
of cellular localization greatly widens the 
spectrum of target antigens including truly 
cancer- specific mutant antigens, so called 
‘neoantigens’, derived from somatic muta-
tions that are acquired in the course of tumor 
development.10
Among all cancer- associated somatic muta-
tions, oncogenic driver mutations are obvi-
ously the most attractive targets for TCR gene 
therapy. A prerequisite for TCR- based thera-
pies is that the mutation leads to generation 
of peptides presented on MHC molecules 
with high affinity.11 12 Selection of antigen- 
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oncogenic transformation. However, many driver muta-
tions such as common p53 mutations occur at many vari-
able positions of a given protein, creating a large number 
of potential target epitopes, which would need to be 
addressed individually. In contrast, a missense mutation 
almost consistently changing leucine in position 265 to 
proline (L265P) in the MyD88 adaptor protein is one 
of the most common driver mutations found in about 
one- fifth of all lymphoid malignancies. MyD88 L265P 
is the hallmark mutation in Waldenström macroglob-
ulinemia, but it is also frequently found in aggressive 
B- cell lymphomas, for example, 30% of activated B cell 
(ABC)- like DLBCL, 45%–60% of central nervous system 
lymphomas and testicular lymphomas,13–16 diseases with a 
huge need for novel specific and well- tolerated therapies.
In this study, we developed high- affinity TCRs recog-
nizing the mutant peptide sequence in MyD88 L265P with 
specific killing capacity towards the mutant malignant 
B- cell population. Targeting cancer- specific genetic alter-
ations with highly specific immunotherapies represents a 
huge step towards precision cellular therapy in oncology.
MATERIALS AND METHODS
In vitro antigen processing and mass spectrometry
Before trying to generate TCRs specific for mutated 
MyD88, we checked whether a peptide spanning the 
mutation is processed by the proteasome and poten-
tially presented by the MHC complex. The polypeptide 
substrate MyD88 L265P256–281 was synthesized by the 
core facility of the Institute of Biochemistry using stan-
dard Fmoc (N-(9- fluorenyl) methoxycarbonyl) meth-
odology (0.1 mmol) on an Applied Biosystems 433A 
automated synthesizer. The peptide was purified by high- 
performance liquid chromatography and analyzed by 
mass spectrometry (ABI Voyager DE PRO). 20S protea-
somes were purified from human red blood cells, in prin-
ciple following the procedure as previously described by 
Textoris- Taube et al.17 Proteasome digests of the synthetic 
MyD88 L265P256–281 polypeptide were performed in 
100 µL of TEAD buffer (20 mM Tris, 1 mM EDTA, 1 mM 
NaN3, 1 mM Dithiothreitol, pH 7.2) over time at 37°C. For 
establishing a full- scale cleavage map, processing times 
were 48 hours. Proteasomal processing of the synthetic 
of polypeptides was performed at a substrate concentra-
tion of 40 µM in the presence of 4 µg 20S proteasome. 
Digested samples of 10 µL were loaded for 5 min onto a 
trap column (PepMap C18, 5 mm×300 µm×5 µm, 100 Ǻ; 
Thermo Fisher Scientific, Massachusetts, USA) with 2:98 
(v/v) acetonitrile:water containing 0.1% (v/v) Trifluoro-
acetic acid at a flow rate of 20 µL/min and analyzed by 
nanoscale LC- MS/MS using an Ultimate 3000 and LTQ 
Orbitrap XL mass spectrometer (Thermo Fisher Scien-
tific). The system comprises a 75 µm inner diameter 
×250 mm nano LC column (Acclaim PepMap C18, 2 µm; 
100 Å; Thermo Fisher Scientific) or a 200 mm PicoFrit 
analytical column (PepMap C18, 3 µm, 100 Å, 75 µm; New 
Objective). The mobile phase (A) is 0.1% (v/v) formic 
acid in water, and (B) is 80:20 (v/v) acetonitrile:water 
containing 0.1% (v/v) formic acid. For elution, a gradient 
3%–45% B in 85 min with a flow rate of 300 nL/min was 
used. Full MS spectra (m/z 300–1800) were acquired on an 
Orbitrap instrument at a resolution of 60,000 (FWHM). 
At first, the most abundant precursor ion was selected 
for either data- dependent collision- induced dissociation 
(CID) fragmentation with parent list (1+, 2+ charge state 
included). Fragment ions were detected in an ion trap 
instrument. Dynamic exclusion was enabled with a repeat 
count of 2 and 60 s exclusion duration. Additionally, the 
theoretically calculated precursor ions of the expected 
spliced peptides were pre- elected for two Orbitrap CID 
(resolution 7500) and higher- energy collisional dissoci-
ation (HCD) (resolution 15,000) fragmentation scans. 
The maximum ion accumulation time for MS scans was 
set to 200 ms and that for tandem mass spectra (MS/MS) 
scans was set to 500 ms. Background ions at m/z 371.1000 
and 445.1200 act as lock mass.
For LC- MS/MS runs using a Q Exactive Plus mass 
spectrometer coupled with an Ultimate 3000 RSLC-
nano (Thermo Fisher Scientific), samples were trapped 
as described previously and then analyzed by the system 
that comprised a 250 mm nano LC column (Acclaim 
PepMap C18, 2 µm; 100 Å; 75 µm Thermo Fisher Scien-
tific). A gradient of 3%–40% B (alternatively 3%–45% 
B) in 85 min was used for elution. Mobile phase A was 
0.1% (v/v) formic acid in water, and mobile phase B was 
80% acetonitrile in water containing 0.1% (v/v) formic 
acid. The Q Exactive Plus instrument was operated in the 
data- dependent mode to automatically switch between 
full scan MS and MS/MS acquisition. Full MS spectra 
(m/z 200–2000) were acquired at a resolution of 70,000 
(FWHM) followed by HCD MS/MS fragmentation of the 
top 10 precursor ions (resolution 17,500, 1+, 2+, 3+, charge 
state included, isolation window of 1.6 m/z, normalized 
collision energy of 27%). The ion injection time for MS 
scans was set to a maximum of 50 ms, automatic gain 
control (AGCs) target value of 1×106 ions and that for 
MS/MS scans was set to 100 ms, AGCs 5×104; dynamic 
exclusion was set to 20 s. Background ions at m/z 391.2843 
and 445.1200 act as lock mass.
Peptides were identified by PD2.1 software (Thermo 
Fisher Scientific) based on their merged MS/MS of CID 
and HCD. Based on the results, further work focused on 
the 10 mer peptide RPIPIKYKAM (figure 1).
Cell lines and generation of target cells
K562 leukemic cell line was cultured in RPMI with 10% 
fetal bovine serum (FBS) and 100 U/mL penicillin/strep-
tomycin. Non- Hodgkin’s lymphoma cell lines SU- DHL-6, 
OCI- Ly3 and TMD8 were cultured in RPMI with 20% FBS 
and 100 U/mL penicillin/streptomycin. OCI- Ly3 and 
TMD8 cells were kindly supplied by groups of Professor 
Clemens Schmitt and Dr Martin Janz (Max- Delbruck- 
Center for Molecular Medicine, Berlin, Germany).
SU- DHL-6, OCI- Ly3, TMD8 and K652 cells do 
not naturally express HLA- 
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HLA- B*07:02- positive target cells, we transduced the cell 
lines with HLA- B*07:02- coding gamma- retroviral vector 
MP71.18 Moreover, K562 cells with or without HLA- 
B*07:02 were virally transduced to express the complete 
length wild- type or mutant (L265P) MYD88—coupled to 
the expression marker green florescent protein (GFP) via 
p2A—and used as artificial target cells.
Generation of mutation-specific T cells
All mutation- specific TCRs were cloned from peripheral 
blood mononuclear cells (PBMCs), isolated from HLA- 
B7- positive healthy donors. Monocytes were separated by 
plastic adherence for generation of dendritic cells (DCs). 
Following 3 days of culture with 800 IU/mL granulocyte- 
macrophage colony- stimulating factor (GM- CSF) and 
10 ng/mL interleukin (IL)-4 in RPMI with 1% human 
serum, immature DCs were cultured overnight with addi-
tion of 10 ng/mL LPS and 50 ng/mL interferon gamma 
(IFN-γ) for maturation. Mature DCs were then loaded with 
mutant peptide (RPIPIKYKAM) and used for priming 
autologous CD8+ naive T cells. After 10 days, cells from 
each well were stained with a streptamer (HLA*B07:02- 
RPIPIKYKAM; IBA GmbH, Germany) or stained for T- cell 
Figure 1 In vitro generation of the MyD88 L265P264–273 neoepitope. Kinetic proteasomal antigen processing experiments 
were performed using the synthetic polypeptide substrate MyD88 L265P256–281. (A) Summary of the peptides generated by the 
proteasome from the polypeptide substrate MyD88 L265P256–281 in an in vitro digest. The complete list can be found in online 
supplemental table 4. (B–D) The generation kinetics of the MyD88 L265P- derived 10 mer neoepitope and its potential N- 
terminally extended precursor peptides are shown. (E) Kinetics of the degradation of the MyD88 L265P- 
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activation markers such as CD137 (4- 1BB) following 
a peptide restimulation. Positively stained wells were 
restimulated with peptide- loaded autologous PBMCs for 
expansion, in case it was necessary to obtain enough cells 
for fluorescence- activated cell sorting (FACS) isolation. 
The methodology for generating mutation- specific T cells 
is shown in figure 2A. This protocol was largely adapted 
from Wölfl and Greenberg.19
Identification of mutation-specific TCRs
Viable, CD8+ and streptamer- positive cells were sorted by 
FACS for total RNA isolation. A representative FACS plot 
is shown in figure 2B. TCR alpha and beta genes were 
amplified via 5′-RACE PCR (SMARTER RACE cDNA 
Amplification Kit; Clontech, Japan) and cloned (Zero 
Blunt TOPO Cloning Kit; Invitrogen/Thermo Fisher 
Scientific, Massachusetts, USA) in competent Escherichia 
coli cells. Multiple bacterial clones from each TCR chain 
were sequenced to analyze T- cell clonality, and domi-
nant sequences were matched to create alpha- beta (αβ)
TCRs for further characterization. Online supplemental 
table 1 shows CDR3 sequences and gene subtypes of 
MyD88 L265P mutation- specific TCRs. Identified variable 
domains (TRBV and TRAV) were combined with murine 
constant domain sequences (mTRBC and mTRAC) for 
experimental characterization of TCRs and synthesized 
on codon optimization (GeneArt, Thermo Fisher Scien-
tific) for expression in human cells. TCR gene cassettes 
encoding the TRBV in combination with a murine TRBC 
and the TRAV in combination with a murine TRAC, 
separated by a p2A signal, were constructed as shown 
in figure 2C. TCR cassettes were cloned into the vector 
pMP71 by restriction site cloning. CD8+ T cells from 
healthy donors transduced with the TCRs were again 
stained with streptamer to test surface expression of the 
TCRs and functionality of αβTCR pairing (online supple-
mental figure 1).
Figure 2 Generation of mutation- specific TCRs. (A) Schematic explanation of methodology for generation of mutation- specific 
T- cell lines. (B) Representative CD137 staining on 6 hours of restimulation with peptide, or streptamer staining for FACS isolation 
of peptide- specific T cells. (C) Construction of TCR gene cassettes. (D) Non- linear curve analysis of IFN-γ response by TCR- 
transduced CD8+ T cells from healthy donors, following coculture with K562 cells that were transduced with HLA*B07:02 and 
loaded with different concentrations of the mutant peptide (RPIPIKYKAM) or the corresponding WT peptide (RLIPIKYKAM). 
Response to the mutant peptide was detectable down to the concentration of 10−4 µg/mL with EC50 values within the nano 
molar (high affinity) range. Mutation- specific TCRs showed more than 10,000- fold higher affinity to the mutant peptide. IFN-γ 
response was measured by ELISA. FACS, fluorescence- activated cell sorting; IFN-γ, interferon gamma; TCR, T- 
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T-cell activation and cytotoxicity analysis
Peripheral CD8+ T cells from HLA- B7- positive (not typed 
for HLA- B7 subtypes) healthy donors were transduced 
to express mutation- specific TCRs. Staining for murine 
TRBC (PE anti- mouse TCR β chain antibody; BioLegend, 
California, USA) was performed to check transduc-
tion efficiency before every experiment, which ranged 
between 25% and 65% of CD8+ T cells. Target cell lines 
were cocultured with TCR- transduced or control T cells 
for 16 hours. IFN-γ secretion was measured by ELISA 
(OptEIA Human IFN-γ ELISA Set; BD Biosciences, New 
Jersey, USA). Cytotoxicity was evaluated by flow cytometry 
analysis after staining of target cells for active caspase-3 
(AF647 Rabbit Anti- Active Caspase-3, BD Biosciences) 
and fixable dead cell stain (LIVE/DEAD Fixable Violet 
Dead Cell Stain, Thermo Fisher Scientific). Target cells 
were gated on GFP- positive as reporter of wild- type or 
mutant MyD88 expression.
Xenograft models
All animal experiments were performed according to 
the institutional protocols and the national laws and 
regulations. Adult female NOG mice (NOD.Cg- Prkdcscid 
Il2rgtm1Sug/JicTac) and hIL2- NOG (NOD.Cg- Prkdcscid 
Il2rgtm1Sug Tg(CMV- IL2)4- 2Jic/JicTac) mice, which due to 
their production of human IL-2 provide better support for 
the growth of adoptively transferred human T cells, were 
acquired from Taconic Biosciences (New York, USA). In 
short, mice were inoculated subcutaneously with 5×106 
OCI- Ly3 or luciferase- expressing TMD8 cells. Once the 
tumors reached the predetermined volume of 100 mm3 
(~2 weeks after injection), OCI- Ly3 tumor- bearing mice 
were treated with intravenous injection of 1×107 TCR- T 
cells, or mock T cells (untransduced) of the same donor, 
or phosphate buffered saline (PBS) as control. TMD8- 
bearing mice were treated similarly on day 7 after tumor 
cell injection. Caliper and bioluminescence measure-
ments were used to monitor tumor growth. Tumor volume 
was calculated with the formula: length×width2/2. Mice 
were sacrificed when tumor size exceeded 1500 mm³ or 
signs of distress was observed as determined in the animal 
experimentation protocol.
Alanine scan for cross-reactivity
To define the TCR- binding motif, a list of peptides 
was created, in which every amino acid residue in the 
mutant epitope was exchanged one by one with alanine. 
All peptides were separately loaded on HLA- B*07:02- 
expressing K562 cells in the concentration of 10 µg/mL 
and cocultured with TCR- T cells for 16 hours. Response 
was measured via IFN-γ ELISA. Results were then analyzed 
using the online tool Expitope20 to screen for motif simi-
larities in the human proteome. Peptides identified to 
have a binding- motif similarity to the original epitope 
were loaded on HLA- B*07:02- expressing K562 cells in 
the concentration of 10 µg/mL for coculture with TCR- T 
cells from three different healthy donors. Reactivity was 
measured via IFN-γ ELISA.
Lymphoblastoid cell line (LCL) scan for alloreactivity
TCR- T cells from three different healthy donors were 
cocultured for 16 hours with immortalized B- LCLs 
expressing a variety of frequent HLA haplotypes (online 
supplemental table 2), with or without prior peptide 
loading. Response was measured via IFN-γ ELISA.
Data sharing
For further information, please contact  oezcan. cinar@ 
charite. de. Supplemental files can be found in the online 
version of this article. Complete length nucleic acid 
and amino acid sequences of TCRs can be found in the 
published patent application: WO 2020/152161 A1.
RESULTS
Mutation-encompassing peptide is processed by human 
proteasome and binds to HLA-B*07:02 with high affinity
We used NetMHC V.4.021 and NetMHCpan V.4.022 for 
screening of peptides spanning the mutation region on 
MyD88 for candidate epitopes, restricted to HLA haplo-
types commonly found in the European population. A 10 
mer peptide (RPIPIKYKAM) harboring a proline residue 
at position 2 which is highly preferred by HLA- B*07:02,23 
the most common HLA- B allele found in Europe and 
North America, was predicted to be a strong binder, 
while the wild- type sequence had very low predicted HLA 
binding affinity (online supplemental table 3). Since it 
is established that the in vitro generation of epitopes by 
20S proteasomes reflects the in vivo situation with high 
fidelity,24 we performed kinetic in vitro proteasome diges-
tion experiments to study the generation of the predicted 
MyD88 L265P264–273 neoepitope from the synthetic 26 mer 
polypeptide substrate MyD88 L265P256–281. A summary of 
the different peptides generated by the proteasome in an 
in vitro digest is shown in figure 1A; the whole list can be 
found in online supplemental table 4. Giving confidence 
that the predicted 10 mer neoepitope is indeed gener-
ated, mass- spectrometric analysis of the proteasomal 
digests identified the generation of the predicted neoepi-
tope MyD88 L265P 264–273 as well as the generation of two 
N- terminally extended neoepitope precursor peptides 
MyD88 L265P263–273 and MyD88 L265P262–273 requiring 
trimming by endoplasmic reticulum resident aminopep-
tidases. The kinetic generation of the three peptides is 
shown in figure 1B–D, while the degradation of the 26mer 
substrate is shown in figure 1E.
Isolated TCRs yielded mutation-specific and HLA-restricted 
T-cell activity
Next, we generated peptide- specific T- cell lines against 
this neoepitope by priming naive T cells with autologous 
peptide- loaded DCs from healthy HLA- B7- positive donors 
(figure 2A). These peptide- specific T- cell lines recog-
nized the mutant peptide when restimulated as shown 
by CD137 expression and stained with custom MHC- 
peptide streptamer (figure 2B). We cloned 13 unique 
TCR alpha and beta genes from peptide- 
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of five individual donors (first two digits in TCR names 
indicate donor number; eg, TCR1605 and TCR1610 are 
cloned from the same donor) into the gamma- retroviral 
vector MP71, for expression on primary CD8+ T cells 
(figure 2C). T cells transduced with these TCRs (TCR- T) 
recognized HLA- B*07:02- positive K562 cells loaded with 
mutant peptide with varying functional avidity, while 
the corresponding wild- type peptide was not recognized 
(figure 2D). In addition, the 11 and 12 mer precursor 
peptides (MyD88 L265P263–273 and MyD88 L265P262–273) 
detected in mass- spectrometric analysis were also recog-
nized by TCR- T cells (online supplemental figure 2).
To further assess specificity and functionality, we cocul-
tured TCR- T cells with engineered HLA- B*07:02- positive 
or HLA- B*07:02- negative K562 target cells expressing 
the complete wild- type or mutant MYD88 gene. Flow 
cytometric analysis showed mutation- specific and HLA- 
restricted recognition of target cells without exogenous 
peptide loading, proving that the epitope can be gener-
ated from endogenously expressed MyD88 and presented 
by HLA- B*07:02 at the cell surface (figure 3A). Seven 
out of 13 peptide- specific TCRs showed strong reactivity 
against target cells (figure 3C). In addition, the amount 
of IFN-γ secreted by TCR- T cells on target recognition 
correlated with previously measured TCR avidity. The 
highly specific recognition of target cells observed here 
has also led to cytotoxic T- cell activity (figure 3B,D). The 
TCR with the highest overall activity in the comparative 
assessment was TCR2304. TCR2304 was thus chosen for 
further development. Hereafter, TCR- T cells refer to 
TCR2304- transduced T cells.
Figure 3 Mutation- specific activity of TCR- T cells. (A) Mutation- specific activation of TCR- T cells against K562 target cells—
virally transduced to express complete length wild- type or mutant (L265P) MyD88 and HLA*B07:02, shown by flow cytometry 
analysis performed after 16 hours of coculture. (B) Viability of HLA*B07:02- positive target K562 cells that were cocultured for 16 
hours with T cells expressing one of the three highest avidity TCRs, analyzed by flow cytometry. The proportions of apoptotic/
dead cells are given in the upper right quadrant. (C) Comparative TCR- T cell response against target K562 cells. IFN-γ response 
measured by ELISA after coculture with K562 cells virally transduced to express complete length WT or mutant (L265P) MyD88 
(mutation+) and/or HLA*B07:02 (HLA- B7+) as indicated. K562 cells loaded with the mutant peptide served as control (peptide+). 
Thirteen different TCRs were listed according to their respective EC50 values to the mutant peptide titration, from highest to 
the lowest. (D) Viability of target cells for cytotoxicity analysis of T cells transduced with three highest avidity TCRs. Strength of 
cytotoxicity as well as IFN-γ response against target cells strongly correlated with TCR avidity, previously measured by IFN-γ 
response to peptide titration. IFN-γ, interferon gamma; TCR, T- 
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T cells engineered to express TCR2304 recognize and kill 
MyD88 L265P expressing lymphoma cells
To investigate the functional potential of TCR2304 when 
MyD88 L265P is expressed at natural expression levels, we 
analyzed the T- cell response against B- cell lymphoma cell 
lines. We used SU- DHL-6 (GCB- like DLBCL, wild- type 
MyD88), OCI- Ly3 (ABC- like DLBCL, homozygous L265P 
mutation) and TMD8 (ABC- like DLBCL, heterozygous 
L265P mutation) (figure 4A). Since all three cell lines orig-
inated from HLA- B7- negative patients, they were trans-
duced to stably express the HLA*B07:02 gene. Surface 
expression of HLA*B07:02 measured by flow cytometry 
was comparable to primary peripheral blood cells and 
to the HLA- B*07:02- positive B- LCL STA01 (figure 4B). 
Figure 4 Mutation- specific activity of TCR- T cells against DLBCL cell lines with intrinsic MyD88 L265P expression. (A) 
Genomic sequence and allele- specific (AS) PCR analysis of lymphoma cell lines: SU- DHL-6 (GBC- like DLBCL, WT MyD88), 
OCI- Ly3 (ABC- like DLBCL, homozygous MyD88 L265P) and TMD8 (ABC- like DLBCL, heterozygous MyD88 L265P). (B) Side- 
by- side comparison of HLA*B07:02 expression of virally transduced lines versus natural expression in PBMCs isolated from 
an HLA*B07:02- positive donor and an HLA*B07:02- positive B- LCL line (STA01) measured by flow cytometric staining. (C) 
Activation analysis of TCR2304- transduced T cells via IFN-γ ELISA, after 16 hours of coculture with lymphoma cells. Cell lines 
virally transduced to express HLA*B07:02 are shown as ‘cell line_B7’. Results from two different blood donors plotted with error 
bars showing SD significance analysis by two- way ANOVA: ****p<0.0001. (D) Representative flow cytometric viability analysis 
of lymphoma cells expressing HLA*B07:02 after 16 hours of coculture with T cells (as explained in figure 3). (E) Viability analysis 
of lymphoma cells with or without HLA*B07:02 expression. T cells of three different donors were used, error bars with SD 
significance analysis by two- way ANOVA: ***p<0.001, ****p<0.0001. (F) Antigen- induced proliferation of TCR2304- transduced T 
cells following 72 hours of coculture with HLA*B07:02- positive OCI- Ly3 and TMD8 cells. T cells were labeled with CFSE to trace 
proliferation prior to coculture. ANOVA, analysis of variance; DLBCL, diffuse large B- cell lymphoma; IFN-γ, interferon gamma; 
PBMC, peripheral blood mononuclear cell; TCR, T- 
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Overnight coculture with these lymphoma cells led to 
activation of TCR- T cells (figure 4C), which was accompa-
nied by mutation- specific cytotoxicity (figure 4D,E) and 
T- cell proliferation (figure 4F). Specific T- cell response 
and cytotoxicity against naturally mutant lymphoma cells 
provided further evidence for the functional potential of 
TCR2304.
Myd88 L265P-redirected TCR-T cells induce durable 
regression of human lymphoma xenografts in mice
Having observed a strong specific T- cell response against 
MyD88 L265P mutant B- cell lymphoma lines in vitro, 
we tested TCR2304 in vivo for further assessment of its 
therapeutic potential. For this purpose, we generated 
a xenograft model by subcutaneously injecting HLA- 
B*07:02- expressing OCI- Ly3 cells into immunodeficient 
NOG mice. After tumors reached the predetermined size 
of 100 mm3, mice were randomly treated with a single 
intravenous injection of 1×107 TCR- T or mock T cells, or 
PBS as untreated control. All untreated or mock- treated 
mice showed progressive tumor growth that required 
sacrificing the mice between days 13 and 37 (figure 5A). 
Four of the six mice that received TCR2304- T cells 
showed complete remission of the tumor, with tumor 
shrinking beginning between days 18 and 25 after T- cell 
application, although in one of these mice the tumor 
started to regrow around day 40. Two mice needed to 
be sacrificed early in the experiment due to rapid tumor 
progression and severe symptoms of disease before 
TCR- T cells could take effect. Since human T cells grow 
poorly without support from human cytokines, we also 
used the same tumor model in hIL2- NOG (immunodefi-
cient NOG mouse expressing human IL-2 cytokine). This 
model is expected to have an enhanced T- cell engraft-
ment and has been shown to improve the outcome from 
T- cell therapy.25 Indeed, tumors in hIL2- NOG mice 
that received TCR- T cells disappeared completely after 
3 weeks and did not relapse after up to 2 months following 
treatment (figure 5B).
To evaluate the mechanisms leading to tumor regrowth 
after initial response, the NOG mouse that had shown 
Figure 5 Therapeutic efficacy of TCR- T cells in OCI- Ly3 xenograft mouse models. NOG and hIL2- NOG mice were 
subcutaneously injected with 5×106 HLA*B07:02 expressing OCI- Ly3 cells. Treatment with 1×107 T cells was given by 
intravenous injection after tumors reached the predetermined size of 100 mm3. (A) Change of tumor volume (significance 
analysis by two- way ANOVA, showing difference of tumor volume on day 31: ***p<0.001) and survival after treatment start in 
NOG mice. (B) Change of tumor volume after treatment start in hIL2- NOG mice. Significance analysis by two- way ANOVA, 
showing difference on day 30: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (C) Flow cytometric analysis of T cells in tissues of 
TCR- T cell- treated common NOG and hIL2- NOG mice, 58 days after treatment. (D) PD-1 expression in TCR- T cells in tissues of 
hIL2- NOG and common NOG mice on day 58 after treatment start, analyzed by flow cytometry. ANOVA, analysis of variance; IL, 
interleukin; TCR, T- 
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tumor regrowth starting on day 40 was sacrificed on day 
58 together with a mouse that had continuing response 
from the hIL2- NOG TCR- T treated group. We observed 
that the hIL2- NOG mouse still had a high amount of 
human T cells in blood, bone marrow and spleen, while 
the NOG mouse had only some T cells remaining in 
the tumor (figure 5C). TCR- T cells from tissues of the 
hIL2- NOG mouse did not show any significant change 
in the exhaustion marker PD-1 (programmed cell death 
protein 1), while TCR- T cells remaining in the growing 
tumor of the NOG mouse showed increased PD-1 staining 
in flow cytometric analysis (figure 5D).
However, in a second series of experiments using 
hIL2- NOG mice, some of the animals died independently 
of the size of the tumor. We had hints that these mice 
were developing severe graft- versus- host disease (GvHD) 
by proliferating human T cells, as reported by Ito et al.26 
The amount of GvHD- related toxicity indeed varied 
significantly using different human donors; therefore, we 
decided to stop further experiments in this model.
To validate our findings in a second model, luciferase- 
expressing HLA- B*07:02- positive TMD8 cells were 
subcutaneously injected into NOG mice, yet it caused 
some mice to die early due to strong systemic dissemi-
nation and aggressive tumor progression before treat-
ment could be administered. Therefore, we decided to 
treat TMD8 bearing NOG mice 7 days after tumor inoc-
ulation. Indeed, on these experimental conditions, the 
T- cell treatment led to a significant reduction in tumor 
size starting at day 24 (figure 6A,B). Furthermore, TCR- T 
cell treatment prevented systemic dissemination of TMD8 
cells (figure 6C,D and online supplemental figure 3).
Again, data in hIL2- NOG mice were complicated by 
T- cell toxicity caused by human versus mouse GvHD, which 
differed from experiment to experiment depending on 
different human donors, and although these experi-
ments largely confirmed activity of transduced T cells in 
controlling tumor growth, they are not presented here.
TCR2304 is highly specific for the MyD88 L265P mutation 
without off-target reactivity
Even though all TCRs described in this study were 
isolated from healthy HLA- B7- positive donors and thus 
passed thymic selection, the risk of cross- reactivity against 
other human proteins is still potentially present. Peptides 
generated in the alanine scan were loaded separately on 
HLA- B*07:02- expressing K562 cells and cocultured with 
TCR- T cells to define the amino acids that are essential 
for the recognition (binding motif) by different TCRs 
(online supplemental figure 4). The proline in position 
2, which reflects the amino acid substitution L265P in 
mutant MyD88, as well as the tyrosine in position 7, turned 
out to be essential for all TCRs, demonstrating the spec-
ificity of the TCRs for the mutation. Following detection 
of the binding motif (online supplemental figure 5A), we 
assessed the possibility of cross- reactivity to other human 
proteins, which might be caused by binding- sequence 
similarity, using the online tool Expitope.20 In the case 
of TCR2304, the screen revealed 26 human peptides 
exhibiting motif similarity (xPxxIxYxxx) with up to five 
amino acid mismatches: 12 of these had some predicted 
binding affinity to HLA- B*07:02 on NetMHC V.4.0 and/
or NetMHCpan V.4.0 (online supplemental figure 5). We 
tested TCR- T cells against all 12 peptides loaded on HLA- 
B*07:02- positive K562 cells in high concentration (10 µg/
mL) in a coculture. However, no meaningful response 
was observed (online supplemental figure 5B).
For assessment of alloreactivity, we cocultured TCR- T 
cells with a panel of 16 Epstein- Barr virus- immortalized 
B- LCLs, which covered a broad spectrum of HLA haplo-
types and most of the frequent HLA alleles found in 
Europe (Online supplemental table 2). When compared 
with untransduced control T cells, overnight coculture 
only demonstrated significant TCR- T cell response when 
HLA- B7- positive cell lines were externally loaded with 
mutant peptide (online supplemental figure 5C). Thus, 
we did not observe any sign of alloreactivity in this setting.
DISCUSSION
Contrary to CAR- T cell- based approaches, TCR- based 
cellular therapy has not yet led to breakthrough clinical 
results. However, because of the promise of cancer speci-
ficity, targeting tumor- specific neoepitopes by TCR gene 
therapy is continuing to attract attention. In solid tumors, 
TCRs directed against patient- individual mutations but 
also against a few recurrent mutations have been success-
fully isolated. First trials targeting mutant KRAS are 
currently recruiting.27 28
In this study, we present strong preclinical evidence that 
the lymphoma- associated L265P point mutation of MyD88 
creates suitable neoepitopes for HLA- presentation, elic-
iting an efficient mutation- specific T- cell response. We 
have isolated a high- affinity TCR targeting a 10 mer 
neoepitope restricted to HLA- B*07:02, which mediates 
strong in vitro T- cell response against lymphoma cells with 
both homozygous and heterozygous L265P mutations. 
Adoptive transfer of gene- modified TCR- T cells shows 
promising therapeutic effect in preclinical experiments 
using human xenografts in immune- deficient mice. Our 
data indicate that the mutant epitope can indeed serve 
as a rejection antigen. In addition, preliminary safety 
screening does not indicate off- target activity of the TCR.
In a previous study by Nelde et al in 2017,29 potential 
peptides derived from MyD88 L265P had been analyzed 
and shown to generate T- cell responses restricted to 
HLA- B*07:02 and HLA- B*15:01. Peptide- specific T cells 
reported in their study showed cytotoxic reactivity against 
peptide- loaded target cells, and it was suggested that 
these peptides may be used for a peptide- based immu-
notherapy approach, in case the peptides are naturally 
processed and presented. A separate study by Nielsen et 
al30 in the same year confirmed that one of the mentioned 
peptides restricted to HLA- B*07:02 induced a mutation- 
specific T- cell response, and data suggested that the target 
epitope is endogenously processed. Peptide- 
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cells against this HLA- B*07:02- restricted epitope were 
only detected in one out of six donors, hinting that a 
peptide- based immunotherapy approach may not elicit 
autologous immunity in the majority of patients.
In vitro antigen processing experiments, generating 
linear non- spliced peptides, are accepted to mirror the 
in vivo situation with high fidelity.24 In our work, we show 
that the HLA- B*07:02 10 mer neoepitope is generated 
in vitro and that we also could generate strong T- cell 
responses in 5 out of 24 donors. However, only a few of 13 
isolated and cloned TCRs from these five donors showed 
high affinity for the mutated peptide—demonstrating 
reactivity in the nanomolar range, which is thought to be 
crucial to achieve a therapeutic antitumor effect.31 Our 
high- affinity TCR elicited strong therapeutic activity in a 
preclinical mouse model, suggesting that the sequence 
of a high- affinity TCR could be used ‘off the shelf’ to 
generate a highly specific, individualized yet broadly 
applicable ATT product usable in all HLA- B*07:02- 
positive patients whose tumors carry the L265P mutation. 
In our opinion, such a treatment could fulfill in an ideal 
way the criteria for precision cancer therapy.
A main limitation to TCR gene therapy is the impaired 
MHC–peptide presentation in cancer cells. Mutations in 
the processing and presentation machinery, or downregu-
lation of MHC molecules on the cell surface, is described 
in solid cancers and also in lymphomas.32 33 However, this 
rarely affects all malignant cells in a tumor and rarely 
Figure 6 Therapeutic efficacy of TCR2304- T cells in TMD8 xenograft mouse model. NOG mice were suncutaneously injected 
with 5×106 TMD8 cells that are stably transduced with HLA*B07:02 and firefly luciferase. Tumor growth was detectable via 
bioluminescence imaging in all mice as early as day 2. (A) Change of tumor volume over time (error bars plotted with SEM 
significance analysis by two- way analysis of variance, showing difference on day 24: **p<0.01) and survival of NOG mice after 
treatment start. (B) Bioluminescence images of tumor- bearing mice at days 18 and 25 after treatment. Exposure: 60 s. (C) Flow 
cytometric analysis of systemic dissemination: proportion of TMD8 cells in tissues of tumor- bearing NOG mice. Human cells 
meaning sum of TMD8 lymphoma cells and human T cells. (D) Representative staining of blood samples from tumor- 
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results in a total loss of HLA antigens. IFN-γ secretion by 
even a few specific T cells engaging tumor might be able 
to transform the tumor microenvironment,34 inducing 
MHC upregulation and possibly enhancing the suscepti-
bility of tumor cells to further TCR- T cells migrating into 
the tumor.35
In this respect, the difference we observed between 
hIL2- NOG and normal NOG mice is remarkable: NOG 
mice, in which T- cell proliferation is not supported by IL-2, 
showed some T- cell infiltration in tumors after adoptive 
transfer of MyD88 L265P- specific TCR- T cells, but tumors 
in some mice eventually regrew. Thus, it appears that 
besides lack of cytokine support for T- cell proliferation, 
upregulation of checkpoint inhibitory signals in T cells 
may have contributed to this result. Recent studies36 37 
have shown that MyD88- mutant lymphomas exhibit high 
level expression of the immune- checkpoint mediator 
PD- L1, thus possibly preventing their efficient clearance 
by adaptive host immunity. Conversely, these mutant- 
specific dependencies were therapeutically exploitable by 
anti- PD1 checkpoint blockade. On the other hand, mice 
where T- cell growth is supported by IL-2 stay in remission. 
Experiments in human IL-2 transgenic mice, however, are 
complicated by strong GVHD effect of human T cells with 
strong variations in the severity of GVHD from donor to 
donor; therefore, only a limited number of experiments 
were performed using this model. We think that in an 
appropriate clinical setting where autologous transduced 
T cells likely encounter cytokine support—particularly 
if administered after lymphodepletion—escape mech-
anisms could be avoided. A combination of adoptive 
transfer of mutation- specific TCR- T cells with immune- 
checkpoint blockade38 might also be considered in a 
second phase of a pilot study.
We have tested our TCR in xenografted tumors but 
considered using a syngeneic lymphoma model with 
conditional MyD88 L265P mutation.39 However, these 
mice would have to be crossed to humanized HLA- 
B*07:02 mice,40 which is time consuming. More impor-
tantly, the information provided by such a model would 
be limited with respect to issues of safety and toxicity of 
the TCR in a clinical context, which is eventually crucial 
before moving to a clinical trial. This being our prior 
issue, we have extensively evaluated our TCR for poten-
tial toxicity. Based on our experience with generation of 
TCRs for ATT, we are confident that major reactivities 
can be excluded based on our LCL reactivity and alanine 
scan experiments. Moreover, while a number of TCRs are 
generated in transgenic mice for other targets with some 
of them already being approved by regulatory author-
ities for testing in clinical trials,41 42 TCRs described 
in this study were generated from healthy humans—
without further modifications to enhance affinity—and 
had undergone thymic selection, thus at least theoreti-
cally further reducing the risk of unwanted recognition 
of self- proteins. Further safety testing, such as reactivity 
studies using larger cell line and tissue libraries or the use 
of amino acids other than alanine in amino acid replace-
ments,43 has been proposed and will be discussed with 
safety authorities if required in preparation of a clinical 
trial.
We believe that besides CAR- T cell therapy, which has 
become a tremendous tool for the treatment of poor prog-
nosis lymphomas and leukemias, there is a great potential 
in the use of TCR- T cell therapy. Our study provides a 
strong base for such a highly tumor- specific, molecularly 
defined TCR- based immunotherapy in selected hemato-
logical malignancies.
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